Popular Trials
Cancer Vaccine
Self-Collection Screening for Cervical Cancer Prevention
This trial aims to prevent cervical cancer in Kenyan women by combining screening for premalignancies and vaccinating children against HPV. Currently, only a small percentage of women are regularly screened, and very few
Popular Filters
Trials for Cancer Patients
Monoclonal Antibodies
NPX267 for Cancer
This trial tests NPX267, an antibody drug that helps the immune system fight cancer by targeting a specific marker on cancer cells. It focuses on patients with certain cancers, including a type of lung cancer, to find a safe and effective dose. The study will monitor side effects and check how well the drug works against tumors.
CAR T-cell Therapy
E7 TCR-T Cells for HPV-Related Cervical and Throat Cancer
This trial tests a new treatment using modified immune cells to fight cancers caused by HPV. It targets patients with specific types of cancer linked to HPV who have a certain genetic marker. The treatment works by reprogramming the patient's immune cells to attack the cancer cells.
Trials for Breast Cancer Patients
Monoclonal Antibodies
MK-7684A for Advanced Cancers
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
Small Molecule Kinase Inhibitor
Tucatinib + Trastuzumab for HER2-Positive Cancers
This trial is for people with solid tumors that make too much HER2 or a different type of HER2. Participants will get tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get fulvestrant. The trial will look at side effects.
Monoclonal Antibodies
SGN-B6A for Cancer
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
CAR T-cell Therapy
TCR-T Cell Therapy for Cancer
This trial tests a new treatment using modified immune cells to target specific cancers. It focuses on patients with certain metastatic cancers that produce an abnormal protein. The treatment aims to use the body's own enhanced immune system to fight cancer.
Trials for Metastatic Patients
Monoclonal Antibodies
MK-7684A for Advanced Cancers
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
Small Molecule Kinase Inhibitor
Tucatinib + Trastuzumab for HER2-Positive Cancers
This trial is for people with solid tumors that make too much HER2 or a different type of HER2. Participants will get tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get fulvestrant. The trial will look at side effects.
Monoclonal Antibodies
SGN-B6A for Cancer
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Monoclonal Antibodies
Pembrolizumab + Chemoradiotherapy for Cervical Cancer
This trial will compare the effectiveness of two cancer treatments for locally advanced cervical cancer. The first treatment is pembrolizumab plus concurrent chemoradiotherapy and the second is placebo plus concurrent chemoradiotherapy. The study's primary hypotheses are that pembrolizumab plus concurrent chemoradiotherapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival and overall survival.
Antibody-Drug Conjugate
Tisotumab Vedotin Combinations for Cervical Cancer
This trial is testing a new cancer drug called tisotumab vedotin. The trial has two parts: a dose escalation part and an expansion part. The expansion part will start once the Recommended Phase 2 Dose (RP2D) of the combinations have been determined in the dose escalation part.
Phase 3 Trials
Monoclonal Antibodies
Pembrolizumab + Chemoradiotherapy for Cervical Cancer
This trial will compare the effectiveness of two cancer treatments for locally advanced cervical cancer. The first treatment is pembrolizumab plus concurrent chemoradiotherapy and the second is placebo plus concurrent chemoradiotherapy. The study's primary hypotheses are that pembrolizumab plus concurrent chemoradiotherapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival and overall survival.
Platinum-based Chemotherapy
Chemo-Radiation for Early-Stage Cervical Cancer
This trial is studying how well giving chemotherapy and pelvic radiation therapy together with or without additional chemotherapy works in treating patients with high-risk early-stage cervical cancer.
Virus Therapy
Volrustomig for Advanced Cervical Cancer
This trial is testing a new medication called Volrustomig to see if it can help women with advanced cervical cancer. The study focuses on those who haven't seen their cancer progress after initial treatment. Volrustomig might help stop or slow down the growth of cancer cells.
Trials With No Placebo
Monoclonal Antibodies
MK-7684A for Advanced Cancers
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
Small Molecule Kinase Inhibitor
Tucatinib + Trastuzumab for HER2-Positive Cancers
This trial is for people with solid tumors that make too much HER2 or a different type of HER2. Participants will get tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get fulvestrant. The trial will look at side effects.
Behavioral Intervention
Cervical Cancer Screening Program for Asian American Women
This trial will evaluate whether providing a self-sampling kit along with an educational program and navigation assistance increases cervical cancer screening rates in underserved Korean and Vietnamese American women.
Monoclonal Antibodies
SGN-B6A for Cancer
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
View More Related Trials
Frequently Asked Questions
Introduction to cervical cancer
What are the top hospitals conducting cervical cancer research?
Cervical cancer, a condition that affects thousands of women each year, has prompted top hospitals across the United States to conduct innovative clinical trials. Leading the charge is Houston's M D Anderson Cancer Center, with eight ongoing trials dedicated to cervical cancer and an impressive 30 completed studies since their maiden trial in 2005. Meanwhile, at the University of Virginia in Charlottesville, researchers are actively engaged in five clinical trials for cervical cancer treatment. Their commitment to finding new solutions began back in 2001 when they initiated their first recorded trial on this disease.
Notably, Memorial Sloan Kettering Cancer Center in New york City has been making significant contributions as well. With four ongoing cervical cancer trials and a notable history of conducting 15 previous investigations since their inaugural trial back in 1994. Another institution committed to advancing knowledge about cervical cancer is the University of Alabama at Birmingham Cancer Center; they have four active clinical trials currently underway and have already conducted seven previous studies after starting their pioneering investigation on this disease ten years ago (in 2009). Last but not least, we find the University of Oklahoma Health Sciences Center located in Oklahoma City - contributing significantly towards our understanding and treatment options regarding cervical carcinoma through its current participation involving four active clinical tests while having contributed twenty-three different experiments which can be traced back nearly thirty years (their earliest recorded trial being held way back until1992).
These esteemed hospitals showcase dedication and collaboration within the medical community as they join forces to combat cervical cancer. Each study brings us one step closer toward improved prevention methods, more effective treatments, and ultimately higher survival rates for those affected by this potentially devastating condition.
Which are the best cities for cervical cancer clinical trials?
When it comes to cervical cancer clinical trials, several cities emerge as key players in advancing research and treatment options. Houston, Texas leads the pack with 28 active trials investigating treatments like Sentinel Lymph Node Biopsy, Cemiplimab, Pembrolizumab/Vibostolimab Co-Formulation, among others. Anchorage, Alaska closely follows with 27 ongoing studies examining interventions such as Nivolumab, Cisplatin, Subprotocol C2 (MET exon 14 deletion/mutation), and more. Toronto, Ontario is also notable with 15 active trials exploring Pembrolizumab/Vibostolimab Co-Formulation and ASTX660 alongside other potential breakthroughs. These cities offer individuals battling cervical cancer access to innovative clinical trials that pave the way for advancements in care and hope for improved outcomes.
Which are the top treatments for cervical cancer being explored in clinical trials?
Clinical trials are paving the way for advancements in cervical cancer treatment, with several promising options currently under exploration. These top treatments include:
-
Pembrolizumab: A breakthrough drug, listed in 2016, that has attracted significant attention with its involvement in three active clinical trials and a total of 14 all-time trials dedicated to cervical cancer.
-
Cisplatin: This well-established treatment option, first listed back in 2001, continues to shine with its participation in three ongoing trials and an impressive history of 74 all-time clinical trials focused on combating cervical cancer.
-
Quality-of-Life Assessment: Recognizing the importance of holistic care, quality-of-life assessments have become integral components of cervical cancer research. With three active trials and a cumulative count of 15 all-time studies since their introduction in 2007.
-
KK-LC-1 TCR-T cells: A newcomer to the scene but showing potential promise. First introduced this year (2022), it is currently being investigated through one active trial as part of innovative efforts to revolutionize cervical cancer treatment.
With each study bringing us closer to improved outcomes for patients battling this disease, these top treatments offer hope for a brighter future against cervical cancer.
What are the most recent clinical trials for cervical cancer?
Exciting advancements are underway in the field of cervical cancer research, with recent clinical trials offering promising prospects for patients. Among these trials is Arm B, which investigates a combination of clinic-based and at-home treatments for cervical cancer. Additionally, NPX267 has shown potential as a treatment option in Phase 1 trials for this challenging disease. Sacituzumab Govitecan also holds promise based on its positive outcomes observed in Phase 2 studies. Furthermore, CTX131 has entered both Phase 1 and Phase 2 to evaluate its efficacy against cervical cancer. Lastly, E7 TCR-T cells have demonstrated encouraging results in Phase 2 investigations as a potential therapeutic approach. These ongoing efforts bring hope to those affected by cervical cancer and mark significant progress towards better treatment options.
What cervical cancer clinical trials were recently completed?
In recent years, a multitude of clinical trials have been completed in the pursuit of advancements against cervical cancer. Noteworthy among these is the successful completion in October 2020 of a trial exploring NKTR-255, led by Nektar Therapeutics. Another significant milestone was achieved through an investigation into Bevacizumab sponsored by EMD Serono Research & Development Institute, Inc., also completed in October 2020. Furthermore, AK104 underwent testing with sponsorship from Akeso and concluded its trial in July 2020. These achievements represent vital steps forward as researchers persistently strive to improve treatments for cervical cancer patients.